biOasis Receives Compelling Data From Texas Tech University On Its Herceptin(R) BT2111 Program - Yahoo! Finance

biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that research underway at Texas Tech University Health Sciences Center (TTUHSC) has yielded some compelling data on preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of Transcend and Herceptin®) in animal models of breast cancer metastasis to the brain.

Read the full story >>

Story produced by the Office of Communications and Marketing, (806) 743-2143.